Authors:
Schwaab, T
Lewis, LD
Cole, BF
Deo, Y
Fanger, MW
Wallace, P
Guyre, PM
Kaufman, PA
Heaney, JA
Schned, AR
Harris, RD
Ernstoff, MS
Citation: T. Schwaab et al., Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI Xanti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu, J IMMUNOTH, 24(1), 2001, pp. 79-87
Authors:
Cole, BF
Gelber, RD
Gelber, S
Coates, AS
Goldhirsch, A
Citation: Bf. Cole et al., Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis, LANCET, 358(9278), 2001, pp. 277-286
Authors:
Lewis, LD
Cole, BF
Wallace, PK
Fisher, JL
Waugh, M
Guyre, PM
Fanger, MW
Curnow, RT
Kaufman, PA
Ernstoff, MS
Citation: Ld. Lewis et al., Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu, J IMMUNOL M, 248(1-2), 2001, pp. 149-165
Authors:
Schwaab, T
Heaney, JA
Schned, AR
Harris, RD
Cole, BF
Noelle, RJ
Phillips, DM
Stempkowski, L
Ernstoff, MS
Citation: T. Schwaab et al., A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha 2b therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters, J UROL, 163(4), 2000, pp. 1322-1327
Authors:
Mounier, N
Haioun, C
Cole, BF
Gisselbrecht, C
Sebban, C
Morel, P
Marit, G
Bouabdallah, R
Ravoet, C
Salles, G
Reyes, F
Lepage, E
Citation: N. Mounier et al., Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission, BLOOD, 95(12), 2000, pp. 3687-3692
Citation: Dl. Brown et al., More about: Multifactorial analysis of differences between sporadic breastcancers and cancers involving BRCA1 and BRCA2 mutations - Response, J NAT CANC, 91(16), 1999, pp. 1422-1422
Citation: Dl. Brown et al., Multifactorial analysis of differences between sporadic breast cancers andcancers involving BRCA1 and BRCA2 mutations, J NAT CANC, 91(1), 1999, pp. 90-91
Citation: M. Bonetti et al., A method-of-moments estimation procedure for categorical quality-of-life data with nonignorable missingness, J AM STAT A, 94(448), 1999, pp. 1025-1034
Authors:
Glantz, MJ
Jaeckle, KA
Chamberlain, MC
Phuphanich, S
Recht, L
Swinnen, LJ
Maria, B
LaFollette, S
Schumann, GB
Cole, BF
Howell, SB
Citation: Mj. Glantz et al., A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors, CLIN CANC R, 5(11), 1999, pp. 3394-3402
Authors:
Parsons, SK
Gelber, S
Cole, BF
Ravindranath, Y
Ogden, A
Yeager, AM
Chang, M
Shuster, J
Weinstein, HJ
Gelber, RD
Citation: Sk. Parsons et al., Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group study 8821, J CL ONCOL, 17(7), 1999, pp. 2144-2152
Authors:
Rosendahl, I
Kiebert, GM
Curran, D
Cole, BF
Weeks, JC
Denis, LJ
Hall, RR
Citation: I. Rosendahl et al., Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: Comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer, PROSTATE, 38(2), 1999, pp. 100-109
Authors:
Bensen, SP
Cole, BF
Mott, LA
Baron, JA
Sandler, RS
Haile, R
Citation: Sp. Bensen et al., Colorectal hyperplastic polyps and risk of recurrence of adenomas and hyperplastic polyps, LANCET, 354(9193), 1999, pp. 1873-1874